Adamant Health is a technology company.
Adamant Health is a technology company.
Adamant Health has raised $2.0M across 1 funding round.
Adamant Health has raised $2.0M in total across 1 funding round.
Adamant Health has raised $2.0M in total across 1 funding round.
Adamant Health's investors include HC Services Oy, Voima Ventures.
Adamant Health is a Finnish health‑tech company that builds an AI‑powered measurement and analysis service combining wearable motion sensing with surface electromyography (sEMG) to quantify and track motor symptoms in Parkinson’s disease and other movement disorders[3][1].
High‑Level Overview
Adamant Health develops a clinical measurement and analytics service that fuses wearable kinematic sensors with surface EMG and AI‑driven analysis to deliver objective, longitudinal symptom data for Parkinson’s patients, clinicians, researchers and pharma customers[1][3]. The product is intended to improve clinical decision‑making and personalized therapy (including medication timing and titration), support clinical research and drug development with precise real‑world endpoints, and give patients clearer, actionable information about symptom patterns[1][6]. The company reports strong customer satisfaction (NPS 88) and positions its offering as unique because it measures both visible movement and underlying neuromuscular signals[1][3].
Origin Story
Adamant Health was founded in 2020 as a university spin‑off from research at the University of Eastern Finland (HUMEA lab), based on ~15 years of academic work on neuromuscular and movement measurement led by researchers including Saara Rissanen[3][4][7]. Founders include CEO Paulus Carpelan and CTO/Chief Scientist Saara Rissanen; the idea originated from academic research demonstrating that combining motion data with sEMG yields richer, muscle‑level insight into tremor, rigidity and motor fluctuations than motion alone[4][5][7]. Early traction included peer‑reviewed publications from the university group, pilot clinical studies and partnerships (for example, a collaboration announced with Gerresheimer to combine monitoring and personalized delivery technologies)[5][6].
Core Differentiators
Role in the Broader Tech Landscape
Adamant Health rides multiple converging trends: the shift toward objective, digital biomarkers in neurology; growth in wearable sensing for chronic disease management; and the demand from pharma for reliable, real‑world endpoints in neurodegenerative disease trials[1][5][7]. Timing matters because Parkinson’s care and drug development increasingly require continuous, at‑home measurement to capture medication fluctuations and everyday symptom variability that clinic visits miss[6]. Market forces in their favor include rising investment in digital therapeutics/diagnostics, regulatory openness to digital biomarkers, and unmet clinical need for objective measures of motor fluctuations and treatment response[5][6]. By offering muscle‑level insight, Adamant Health can influence how clinicians titrate therapy, how trials define efficacy, and how remote monitoring becomes standard in movement‑disorder care.
Quick Take & Future Outlook
Near term, expect Adamant Health to expand clinical deployments, deepen pharma trial collaborations, and integrate with drug delivery or therapy‑management platforms (the Gerresheimer collaboration is an example pathway)[6][1]. Key trends that will shape their journey are regulatory acceptance of digital biomarkers as trial endpoints, broader adoption of remote monitoring in neurology, and competition from other wearable/motion‑only solutions—Adamant’s sEMG differentiation will be critical to defend value[5][7]. If they scale clinical validation and regulatory/commercial integrations, their influence could shift Parkinson’s care toward more objective, personalized medication management and accelerate development of therapies by supplying high‑resolution, real‑world efficacy data[1][5].
Quick factual anchors: Adamant Health — Finnish spin‑off from University of Eastern Finland, founded 2020; product = combined motion + surface EMG wearable service with AI analytics for Parkinson’s and other movement disorders[3][7][1].
Sources: Adamant Health website and company pages[1][3], university and industry coverage including Voima Ventures and Neurocenter Finland reporting on the company’s research origins and partnerships[5][7], and press coverage of the Gerresheimer collaboration[6].
Adamant Health has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in June 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2022 | $2.0M Seed | HC Services Oy, Voima Ventures |